Akt phosphorylation at Ser473 predicts benefit of paclitaxel chemotherapy in node-positive breast cancer.
about
The determinants of head and neck cancer: Unmasking the PI3K pathway mutationsRICTOR polymorphisms affect efficiency of platinum-based chemotherapy in Chinese non-small-cell lung cancer patients.Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention.Down-regulation of HtrA1 activates the epithelial-mesenchymal transition and ATM DNA damage response pathwaysExtreme loss of immunoreactive p-Akt and p-Erk1/2 during routine fixation of primary breast cancerNotch1 phenotype and clinical stage progression in non-small cell lung cancerThe Akt signaling pathway: an emerging therapeutic target in malignant melanoma.Role of phosphatidylinositol-3-kinase pathway in head and neck squamous cell carcinoma.PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer.Effects for Sequential Treatment of siAkt and Paclitaxel on Gastric Cancer Cell Lines.The VEGF inhibitor axitinib has limited effectiveness as a therapy for adrenocortical cancer.Association of γH2AX at Diagnosis with Chemotherapy Outcome in Patients with Breast Cancer.Phosphorylation of AKT pathway proteins is not predictive of benefit of taxane therapy in early breast cancer.Differential involvement of the microtubule cytoskeleton in insulin receptor substrate 1 (IRS-1) and IRS-2 signaling to AKT determines the response to microtubule disruption in breast carcinoma cells.Breast Cancer Clinical Trials: Past Half Century Moving Forward Advancing Patient Outcomes.Phosphorylated Akt expression is a prognostic marker in early-stage non-small cell lung cancer.Taxane resistance in castration-resistant prostate cancer: mechanisms and therapeutic strategiesConnexin 43 C-terminus directly inhibits the hyperphosphorylation of Akt/ERK through protein-protein interactions in glioblastomaStudies on the Identification of Constituents in Ethanol Extract of Radix Glycyrrhizae and Their Anti-Primary Hepatoma Cell Susceptibility
P2860
Q30365726-FE2F2BE6-3113-485A-A3F0-9E8081D5852DQ33435610-56703247-3F85-49E1-B68D-A092697D310DQ34103963-EEFB6049-2089-4016-A20F-36B2F267BA84Q34326145-B3732F18-17FE-47B7-A180-F43E7EA23E88Q34989083-0DCE9290-B2D1-43B3-9A4F-BA571A38D0ABQ35129205-2D50121F-BB66-4B3A-8940-32577331CA80Q35911227-DDDBD7D8-F60A-4F53-9164-858855FCE31DQ35994228-4E145593-05BC-4612-AEDB-1462737C4336Q36718459-D1D73722-8A79-4BC4-B188-62809EB43E6BQ37263512-F76D24F4-2E3B-4C0B-81AC-4B786A54A4EEQ37681171-FB660ACC-2469-4D5A-AB04-6D350DE5D3FEQ37738231-598A6447-6F81-47AE-98B1-B0FB3E1D44E8Q38454847-3DC2DA8E-9086-4EDF-80C4-EA442713506CQ38711459-79E91100-DAD2-4D43-B371-DFE6B0C1B82BQ38882550-2790BC2F-43E0-434B-AF1F-D92288665031Q45106879-A3EE6414-FE41-4D3D-9C61-3AB86214D2D7Q57110000-FB63B94A-997C-42D1-90CA-C9CE6E52C3ACQ58792718-E48ABA3A-3414-4E02-8954-0132436EC548Q59055669-C38B9373-B15D-4C46-B10F-8125EA1ECB81
P2860
Akt phosphorylation at Ser473 predicts benefit of paclitaxel chemotherapy in node-positive breast cancer.
description
2010 nî lūn-bûn
@nan
2010 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Akt phosphorylation at Ser473 ...... n node-positive breast cancer.
@ast
Akt phosphorylation at Ser473 ...... n node-positive breast cancer.
@en
type
label
Akt phosphorylation at Ser473 ...... n node-positive breast cancer.
@ast
Akt phosphorylation at Ser473 ...... n node-positive breast cancer.
@en
prefLabel
Akt phosphorylation at Ser473 ...... n node-positive breast cancer.
@ast
Akt phosphorylation at Ser473 ...... n node-positive breast cancer.
@en
P2093
P2860
P50
P356
P1476
Akt phosphorylation at Ser473 ...... n node-positive breast cancer.
@en
P2093
Dat Nguyen
Eleftherios P Mamounas
Jong-Hyeon Jeong
Joseph P Costantino
Norman Wolmark
Sherry X Yang
Soonmyung Paik
P2860
P304
P356
10.1200/JCO.2009.26.1602
P407
P577
2010-05-17T00:00:00Z